Adherence and its Measurement in Phase 2/3 Microbicide Trials by Tolley, Elizabeth E. et al.
SUBSTANTIVE REVIEW
Adherence and its Measurement in Phase 2/3 Microbicide Trials
Elizabeth E. Tolley • Polly F. Harrison • Els Goetghebeur •
Kathleen Morrow • Robert Pool • Doug Taylor •
Stephanie N. Tillman • Ariane van der Straten
Published online: 19 November 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Adherence optimization and measurement have
emerged as critically challenging issues for clinical trials of
topical microbicides. Although microbicide trials have
routinely collected adherence data, their utilization in trial
design, implementation, and interpretation has been
inconsistent. Drawing on data-driven presentations from
several focused meetings, this paper synthesizes lessons
from past microbicide trials and provides recommendations
for future trials of microbicide and other HIV prevention
technologies. First, it describes four purposes for adherence
data collection, with particular attention to intention-to-
treat versus adherence-adjusted analyses for determining
effectiveness. Second, the microbicide ﬁeld’s experiences
with adherence measures and data collection modes are
discussed, including the strengths and weaknesses of var-
ious options and approaches for improving measurement.
Then, several approaches to optimizing trial participants’
adherence are presented. The paper concludes with a set of
recommendations for immediate use or further research.
Keywords Adherence  Microbicides  Clinical trials 
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Background
In the past decade, six topical, vaginally-inserted micro-
bicide products have been evaluated in one or more clinical
trials for their effectiveness in preventing HIV acquisition
in women. As yet, none of the trials have produced con-
clusive evidence of effectiveness. Trials of three products
were inconclusive [1, 2, 3], while two products, COL-1492
[4] and cellulose sulfate [5] were found to potentially
increase the risk of HIV infection. Most recently, one
product [3] has produced a promising, but statistically non-
signiﬁcant result; a recently-completed and larger trial may
provide stronger evidence [6].
Given the lack of clear, positive evidence for an effec-
tive topical microbicide, adherence has emerged as a crit-
ical issue [7]. Yet, improving adherence behavior and its
measurement have proven challenging for reasons both
unique to the ﬁeld of topical microbicides, and shared with
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generally recruit healthy, uninfected individuals who may
have little incentive to adhere to products of unknown
effectiveness [8, 9]. While clinicians ensure product
adherence in vaccine or male circumcision prevention tri-
als, product administration and proper dosing in topical
microbicide trials is generally participant-dependent and
likely to be inﬂuenced by participants’ understanding,
motivations and abilities related to product use. Second,
because no validated biomarkers of adherence exist for
topical microbicides, adherence measurement has relied
largely on self-reports which, for coitally-dependent mi-
crobicides, is further complicated by the need to measure
associated sexual and condom use behaviors. Finally, the
association of these product adherence and risk behaviors
with human sexuality and HIV/AIDS—topics that are
highly stigmatized in most settings, create additional bar-
riers for both the optimization and accurate measurement
of adherence in microbicide trials, as well as HIV treatment
and prevention trials more broadly.
In December 2007, the Alliance for Microbicide
Development (AMD) and Family Health International
convened a 2-day meeting to generate guidance on (1)
methods for measuring sexual and product adherence
behavior in trial contexts and (2) improving design of
clinical trial protocols to optimize adherence to protocol
and product use. Drawing upon presentations from the
December 2007 meeting, the February 2008 Microbicides
2008 International Conference, a November 2006 meet-
ing on Biomarkers for Evaluating Vaginal Microbicides
and Contraceptives co-sponsored by AMD and CON-
RAD, and a recent Institute of Medicine report [10], this
paper reviews reasons for which microbicide trial adher-
ence data may be collected, highlights issues related to
adherence measurement, and discusses approaches to
optimizing adherence. It closes with recommendations for
adherence measurement and optimization that may have
relevance for trials of other female-initiated prevention
methods.
Reasons for Collecting Adherence Data in Microbicide
Trials
Adherence data are routinely collected in microbicide clin-
ical trials, but their utilization in trial design, implementa-
tion, and interpretation has been inconsistent. Because the
purposeofmeasurementwillinﬂuencethetypesofdata,data
collection methods, and/or data sources, it is essential to be
clear about the reasons for collecting such data before
determining how to measure adherence. Those reasons fall
into four categories: (1) determining microbicide effective-
ness, (2) providing additional evidence to support trial
results, (3) understanding safety, and (4) understanding
acceptability and product experience.
Determining Microbicide Effectiveness
Intention-to-Treat (ITT) Analysis
The central design of Phase 3 microbicide clinical trials
assesses the relative reduction in risk of HIV between par-
ticipants randomized either to an active or a control/placebo
product. Primary data analysis typically follows the ITT
principle, whereby each participant is assessed according to
the treatment regimen assigned at baseline, regardless of
post-randomization adherence. If the observed rate of HIV
infectionissigniﬁcantlylowerintheactivethancontrolarm,
then one would conclude that the microbicide being tested
has the intended biological effect of reducing risk of infec-
tion, as long as it could be assumed that the rate of HIV
exposure (which is inﬂuenced by risk-taking behaviors and
alternative protective measures) had been comparable
between study arms (i.e., as would be hoped for in a ran-
domized study with a blinded control arm).
ITT analysis is considered the gold standard for ana-
lyzing randomized clinical trial data because it provides the
basis for an unbiased test of an effect of treatment regimen.
However, because ITT analysis ignores risk-taking
behavior, many consider the generalizability of its con-
clusions to a broader population under routine conditions to
be deﬁcient. Consider the following: (1) If the trial orga-
nizers manage to achieve 100% perfect condom use, there
should be no vaginal transmission of HIV and the inves-
tigators will be unable to demonstrate any effect of the
microbicide—positive or negative. (2) If product use and/
or risk behavior differ between arms, such as the differ-
ential condom use seen in the ‘‘Methods for Improving
Reproductive Health in Africa’’ (MIRA) trial [11], then the
ability to make robust statements about the microbicide’s
biological effect will be undermined. (3) If adherence
happens to be particularly poor during acts where HIV
exposure takes place, then even if the test product is highly
efﬁcacious when used as intended, the reduced ITT effect
will not be detected, even if adherence is quite high overall.
Hence, it is imperative that adherence and risk-taking
behaviors be observed or reported and documented accu-
rately, and their implications for the valid interpretation of
the ITT analysis examined.
Pre-Planned Adherence-Adjusted Analysis
Ideally, if it were possible to know each participant’s
infection status before and after each sex act with an
infected partner, and accurately record the presence or
absence of condom and/or microbicide use for each act,
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powerful approach than an ITT analysis. However, because
the infection status of sexual partners is generally unknown
and participants’ infection status is assessed only infre-
quently, such detailed adherence-based analysis is essen-
tially impossible. Investigators must depend instead on
measures of adherence and risk-taking behavior that can be
applied in those periods between HIV test visits, periods of
varying extent during which the frequency and type of
exposures to HIV cannot be readily known. Nevertheless,
in theory, if a trial could reliably identify women likely to
be adherent prior to their randomization (e.g., based on
data collected during a ‘‘run-in’’ period or on some other
validated predictor of adherence), adherence-adjusted
analysis could still provide convincing, randomization-
based evidence of a test product’s effectiveness in a sub-
group, even if the ITT analysis failed to demonstrate a
protective effect overall [12]. (An appendix, available on-
line, describes the potential for a two-stage biomarker-
adaptive design for microbicide trials.) The potential ben-
eﬁts of such a pre-planned adherence-adjusted analysis
justify efforts to identify valid predictors and measures of
adherence.
Providing Additional Evidence to Support Trial Results
Despite continuing debate about whether adherence data
should be included in primary analyses of effectiveness,
most agree that such data can provide valuable information
to support or explain trial results. For example, if ITT
analysis were to conclude that a new microbicide product
was effective, an unconfounded per-protocol, ‘‘on-prod-
uct’’ analysis would likely ﬁnd a still higher level of
effectiveness, providing insight into the product’s potential
efﬁcacy when used consistently and correctly. Similarly, if
ITT analysis found a suggestive although non-signiﬁcant
reduction in risk—but a noticeably larger effect was
observed in an adherent subset (as occurred in the HPTN
035 trial), then the investigators might be motivated to
conduct a larger, more powerful trial.
In contrast, should an ITT analysis conclude no differ-
ence in infection rates between the active and placebo
arms, several substantially different explanations may
exist. If reported risk-taking behavior were comparable
across arms, and if adherence were found to be high, then
the results were more likely due to a lack of meaningful
product efﬁcacy. On the other hand, if risk factors were not
comparable between arms (as appears to have been the case
with condom use in the MIRA diaphragm trial) [11], then it
may be difﬁcult or impossible to assess product efﬁcacy.
Likewise, if otherwise highly-adherent women tended to
avoid product use in situations when the virus were most
likely to strike (e.g., when having sex with an infected
primary partner), then the product’s potential action was
never tested and no information on efﬁcacy obtained. In the
latter case, even perfect measures of adherence might not
provide sufﬁcient information for drawing unequivocal
conclusions on the relationship between product adherence
and efﬁcacy.
In sum, pre-planned adherence-adjusted analyses that are
notrandomization-basedgenerallycarryariskofmisleading
conclusions. This is acutely the case for clinical trials of
microbicides, where product use is associated with varying
and unpredictable patterns of sexual and risk-taking behav-
ior. This does not mean that adherence-adjusted methods
shouldneverbeundertaken—justthattheymustbeusedwith
cautionand,wherepossible,predicatedonstructuralorother
randomization-based approaches to analysis [13].
Understanding Safety
Evaluating safety is a primary aim of Phase 2 microbicide
trials and a secondary aim of Phase 3 trials. Longer-term
use of any investigational product may affect human safety
as either a direct result of harmful side effects or, indi-
rectly, as a result of changes in participant behavior. For
instance, secondary analysis of adherence data from the
trial of COL-1492, an N-9-based gel, indicated that the
product increased the risk of HIV infection in women who
used it more than 3.5 times daily and who had a high
incidence of lesions with epithelial disruption [13]. Product
use in the context of effectiveness trials may also con-
tribute to negative safety results indirectly if participants,
believing that the test product protects them from HIV
infection, lower their pre-trial levels of condom use or
modify other risk-reduction behaviors [10].
Monitoring Acceptability and Optimizing Adherence
Examining patterns of adherence in the context of an
ongoing clinical trial can lead to insights into product
acceptability that are valuable for the trial itself, for the
design of future trials, and for eventual product introduc-
tion and utilization. Scrutiny of adherence patterns can
reveal who can and cannot use microbicides correctly and
consistently, and what factors enhance or constrain such
use. Better understanding of trial participant perspectives
on the acceptability of the test product and their experience
with it can help implementers optimize adherence as a trial
proceeds. Such understandings will also be relevant to
future product introduction and delivery, and may con-
tribute to fashioning individualized prevention strategies
and identifying and responding to key marketing niches.
Finally, acceptability and adherence data from ongoing and
completed trials can contribute importantly to more real-
istic designs for future trials.
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Anumberofadherencemeasureshavebeenorcouldbeused
in microbicide clinical trials. These fall into three general
categories.Directmeasuresofadherence,oftenreferredtoas
‘‘biomarkers’’, are substances or effects whose presence or
absence indicates that a biological or pharmacological pro-
cess has occurredin response to a drug. Indirect measures of
adherence comprise two major sub-categories: ‘‘objective
measures’’ and ‘‘self-report measures’’, both reliant on the
observations or reports of clinicians, trial participants, or
others. Table 1 presents an overview of these measures, by
category and data collection mode, with their deﬁning
characteristics and the purpose(s) to which they best apply.
Below, we describe these three categories of adherence
measures in greater detail, followed by a brief discussion of
how data collection modes may inﬂuence self-reported
adherence measures, and concluding with potential strate-
gies for improving adherence measurement.
Direct Measures of Adherence
Development of direct, respondent-independent, quantita-
tive biological measures—‘‘biomarkers’’—of adherence
and incident infection might enable the kind of unbiased,
adherence-adjusted effectiveness analyses described in
‘‘Reasons for Collecting Adherence Data in Microbicide
Trials’’. Unfortunately, progress in developing, validating,
and harmonizing such tools has been limited, despite the
urgent need for them in microbicide and other areas of
basic, translational, and clinical research [14, 15, 16].
Biomarkers of Semen Exposure
Prostate-speciﬁc antigen (PSA), semenogelin (Sg), and Y-
chromosome DNA (Yc DNA) have been incorporated into
microbicide-related sub-studies as possible tools for vali-
dating self-reported data on condom use and sexual activ-
ity. Ideally, such biomarkers would be consistently
detectable in the female reproductive tract when exposure
to semen had occurred; have low variability in concentra-
tion levels, physical distribution and time to clearance;
should not be affected by the microbicide under study or
other factors present in the female reproductive tract; and
should be stable, sensitive, speciﬁc, and feasible in a
variety of settings. Their potential for measuring adherence
is presently limited by the fact that semenogelin is
detectable in vaginal ﬂuid samples for only up to 3 days,
PSA only up to 48 h. Furthermore, non-detection of semen
does not necessarily mean that a condom was used during
intercourse; it could also mean that intercourse had either
occurred outside the period of detection or had not occur-
red at all [17, 18].
Applicator Tests
In its Phase 3 trial of Carraguard
, the Population Council
based its primary measure of product adherence on a dye
test intended to indicate whether an applicator had come
into contact with mucins, mucoproteins that are charac-
teristically expressed by female reproductive tract epithe-
lial cells. Participants were asked to return all applicators
distributed to them, whether or not they had been used;
these were then laboratory-processed to reveal a blue stain
if mucin contact had occurred [17]. While such tests could
at least theoretically provide a more objective indicator of
whether returned applicators had been used, they cannot
provide information on the timing of use, the amount of
product inserted, or which mucosal surfaces had been
touched by the applicator. Furthermore, the reliability of
dye tests may vary, depending on the material composition
or form of the applicator.
Drug Level Assays
As work advances on anti-retroviral (ARV)-based topical
microbicides, more adherence measurement options may
become available. Some ARV-based gels are detectable for
days or even weeks after insertion but, as with the Popu-
lation Council’s applicator test, they cannot indicate the
timing of gel insertion in relation to sex, or whether other
coital acts occurred without gel use [17].
Additional Biologic Measures
The International Partnership for Microbicides (IPM) is
developing a bar-coded ‘‘Smart applicator’’ that would
register time and date of use and the ambient vaginal
temperature when the applicator was inserted, and collect
mucin to stain for presence of vaginal secretions but again,
could provide no record of the number of coital acts in
which no applicator—and therefore no product—was used.
IPM is also exploring the potential of a ‘‘Sexometer’’ that
would measure microbicide use during coitus; future pro-
totypes could, theoretically, be designed with sensors to
measure the presence of gel, semen, and virus to determine
exposure to HIV [16]. In sum, despite efforts to develop
and validate biomarkers for use in microbicide clinical
research, technological and practical challenges continue to
limit their use.
Indirect, Objective Measures of Adherence
Measures are considered ‘‘objective’’ when they are inde-
pendent of individual feelings, beliefs, or desires and do
not involve self-report from the subject/participant. In the
case of regimens for product use in clinical trials, such
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123measures have included applicator and pill counts and
electronic drug-monitoring systems.
Applicator counts have been deﬁned as ‘‘objective’’
because they do not rely on participant self-report. Yet
such counts are not totally free of bias since they rely on
clinicians’ accuracy in counting, calculating, and recording
product-use data, and their interpretations of whether or not
an applicator has actually been used. Applicator counts also
depend on participants’ willingness to transport products
between study clinic and home, and on availability of
storage in often spatially constrained domestic environ-
ments with limited privacy. Applicator counts can also
generate under- and over-counting of product use; for
example, counting returned empty gel applicators as
proxies for use-adherence may over-count adherence,
while interpreting failure to return unused applicators as
proxies for adherence may either over- or under-estimate it.
Pill counts have similar limitations. Studies of adher-
ence to antiretroviral therapy have concluded that pill
counts may overestimate adherence if participants either
forget or deliberately fail to bring back all unused product;
electronic drug-monitoring systems like the Medication
Event Monitoring System (MEMS) may underestimate
adherence if participants remove more than one pill from
the bottle at a time. It is also possible that if the MEMS cap
is lost or damaged, data could be compromised in an
unpredictable direction [19, 20].
Indirect, Self-Reported Measures of Adherence
Adherence measurement has more typically been based on
self-reported data and assessed post-randomization. Self-
reported data can be collected through a range of tech-
niques, including face-to-face interviews (FTFI), self-
administered paper or computer-based questionnaires,
diaries, or telephone and text-messaging options. Although
all self-reported data are inﬂuenced by respondents’ ability
to recall and their willingness to provide accurate infor-
mation, choices about data collection mode and question
development may bias responses in different ways. In
addition, adherence questions may vary in terms of time
reference, response format, and/or level of structure.
Time Reference
An individual’s ability to compute estimates of sexual
behavior is inﬂuenced by the frequency of a given behav-
ior, the reporting time frame, and the vividness and com-
plexity of the behavior itself [21]. To date, most
microbicide trials have measured product adherence at last
sex, or as the proportion of sex acts covered during the past
week, rather than the entire 1- to 3-month period between
scheduled follow-up visits, assuming that the more
proximal the time reference, the more accurate partici-
pants’ recall of events.
While a standard approach to adherence measurement
can facilitate comparisons across trials, such truncated time
references may inevitably not be optimal. For example, the
extraordinarily high levels of gel use (97% use at last sex)
reported in the Carraguard
 trial were not conﬁrmed by the
applicator tests, suggesting that participants may have
given ‘‘socially desirable’’ responses or altered behaviors
prior to a forthcoming clinic visit (the ‘‘white coat’’ effect)
in order to align behaviors with reporting expectations [22].
A review of baseline data from seven trials and 27 sites
found wide variation in the mean number of reported sex
acts per week, from one sex act per week in rural South
Africa to almost 27 sex acts per week in Kampala, Uganda
[23]. In populations with high reported coital frequency, a
1-week time frame may be too long for accurate recall.
Conversely, where coital frequency is low, a 1-week time
frame may be too short to accumulate the number of acts
needed for calculating the proportion of risky sex acts.
Exit interviews can reduce response burdens on partic-
ipants and attenuate compulsion toward socially desirable
responses. As one example, 9–15% of MIRA participants
reported at exit that they had ever over- or under-reported
diaphragm and/or gel use in the course of that trial. Still,
while exit interviews do help validate data obtained
through other self-report methods, collecting information
solely at exit presents participants with an increased level
of difﬁculty: having to accurately recall both speciﬁc
behaviors (i.e., sex and product use) and the factors that
had inﬂuenced them [24].
Response Format
Self-reported adherence questions can be worded as fre-
quencies (e.g., number of gel applications in the last week),
proportions (gel use as a proportion of sex acts), binary
categories (use/non-use), or Likert-type scales (e.g.,
always, sometimes, never). While most microbicide trials
have tied adherence measures to speciﬁc sexual episodes,
one sub-study complemented the proportion-based measure
of condom and gel adherence with a second measure based
on participants’ estimates of consistency over a longer
(2-month) time period. Participants were asked whether
they had ever missed using a condom/study gel during sex
and, if so, how often, according to a ﬁve-point scale (never,
rarely, sometimes, frequently, always). While respondents
may liberally interpret Likert-type categories [23], this sub-
study found that the scale of perceived consistency better
differentiated between levels of condom adherence than
did the single measure of condom use as a proportion of
sexual acts. At the study’s 2-month follow-up visit, based
on the measure of condom use as a proportion of sex acts in
1130 AIDS Behav (2010) 14:1124–1136
123the past week, 72% of participants reported 100% condom
use. In contrast, based on the scalar approach, just 42% of
those same participants reported always using a condom,
29% reported sometimes or frequently using a condom, and
29% reporting rarely or never using a condom over the
longer 2-month time frame [25].
Degree of Structure
In-depth interviews (IDIs), focus group discussions
(FGDs), and other qualitative methods are well suited to
investigating complex behaviors and what inﬂuences them.
Indeed, FGDs conducted with participants and their part-
ners exiting from the MIRA trial helped validate quanti-
tative ﬁndings and generated information that proved
critical to understanding differential condom use between
study arms [26]. Nevertheless, qualitative methods gener-
ally require special training and tend to be time-consuming
for participants, researchers, and those who must analyze
the resulting data. Furthermore, they do not address clinical
scientists’ preferences for standardized instruments that
support comparisons across trials, time periods, and
subpopulations.
Psychosocial scales comprising multiple questions or
statements measuring an underlying or latent theoretical
construct (e.g., a measure of protective efﬁcacy or adher-
ence intent) could provide the standardization and ease of
administration desired by clinical researchers; however,
they require adequate pre-trial studies to linguistically and
culturally translate existing measures or develop new ones.
Rigorous methods have been developed for this task,
including: (1) qualitative interviews to generate items and
relevant response sets; (2) cognitive interviews to assess
the ordering, framing, and wording of items; and (3) psy-
chometric evaluation to determine scaling and validity.
Once developed, these measures should be assessed for use
in multiple settings, to be validated across populations and
so that cross-trial data can be accumulated for future meta-
analyses.
Data Collection Modes for Self-Reported Measures
Choice of data collection mode may improve recall, reduce
social desirability bias, or both. Coital and/or product
adherence diaries provide one relatively low-tech approach
to measuring adherence. Computer and telephone-assisted
interview techniques are other potential approaches. All
have their pros and cons.
Diaries can provide a more complete, continuous record
of how products are used during trials. Yet diary-based data
collection is renown for substantial limitations: the need for
some level of participant literacy or numeracy; high par-
ticipant burden; and a documented tendency by participants
to record information in a lagged rather than daily manner,
often just before a study visit.
Audio Computer-Assisted Self-Interview (ACASI) tech-
niques increase privacy and are therefore expected to
decrease social desirability bias, thereby enhancing data
quality and reliability. An interview mode experiment
ancillary to the Carraguard
 trial sought to test this
assertion. The sub-study compared participants’ reports of
sexual and adherence behavior, who had been randomized
either to ACASI or FTFI. Preliminary analysis found sig-
niﬁcantly higher levels of reported sexual risk behaviors
(e.g., number of sexual partners and anal sex) by ACASI
compared to FTFI. In contrast, there were no differences by
data collection mode in the proportion of women reporting
condom or gel use at last sex, reports of condom use in the
prior 2 days, or positive tests for the presence of semen
[27]. Given the required and therefore routinized use of
condoms and gel in a microbicide trial, it is possible that
data collection mode had little bearing on how participants
reported their adherence behavior, whereas the privacy
afforded by ACASI enhanced reporting of more stigma-
tized sexual behaviors.
Despite the potential for increased, possibly more
accurate reporting of some behaviors, ACASI is not with-
out difﬁculties. Separately, some MIRA trial participants
reported confusion about questions and admitted wanting
to complete ACASI questions quickly, suggesting that
participant comprehension and attention may be challenged
by this method and require someone who can help the
participant with clariﬁcations and maintenance of focus
[24]. A pictorial-based application of ACASI, planned for
the ‘‘Vaginal and Oral Interventions to Control the Epi-
demic’’ or VOICE trial [28], may avoid such problems. In
this study, which aims to evaluate the safety and effec-
tiveness of tenofovir (Viread
) and Truvada
 taken orally
as pre-exposure prophylaxis (PrEP) and tenofovir gel
applied vaginally, participants will respond to a sub-set of
questions about sexual behavior and adherence that appear
on the screen in local language text and images, enabling
low-literacy women to respond to key inquiries about
number of sexual partners and tablets, gel, and condom use.
Interactive Voice Response (IVR) technology is another
innovation employed in a Phase 1 microbicide safety study
to collect daily adherence diary data [29]. IVR permits
callers to dial a telephone number that is answered by the
IVR system. A pre-recorded or dynamically-generated
voice explains the interview options and administers
interview questions to which the participant caller responds
by pressing numbers on the telephone keypad or speaking
them into the telephone. Callers are reminded about their
compensation, which is accrued and automatically tallied
at the end of each call. The convenience and privacy
possible through IVR may increase the feasibility of
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decreases social desirability bias. However, gains in pri-
vacy, more frequent follow-up, and quicker access to data
must be balanced with the high cost of programming,
potential loss of data, and lack of participant familiarity
and comfort with technologically complex data collection
methods.
Strategies to Improve Adherence Measurement
Various attempts have been made to enhance and assess the
accuracy of adherence data. These include ‘‘mixed-
method’’ approaches, including triangulation procedures;
development and application of composite measures; and
identiﬁcation of baseline adherence predictors.
Triangulation refers to the use of multiple observers,
theories, or data collection methods to overcome the
inherent biases of any single observer, theory, or method,
increase convergence and reconcile inconsistencies across
data sets. Social scientists used triangulation to identify
adherence-related patterns and problems in the Microbi-
cides Development Programme (MDP) trial 301 in sub-
Saharan Africa. At each of three visits, adherence data
from case record form (CRF) interviews, applicator returns,
and coital diaries were collected on a random subset of 100
women per site and entered into a comparison form. A few
days later, each woman participated in an IDI during which
any inconsistencies in the comparison form were probed.
While some inconsistencies were identiﬁed in over half of
forms, women provided plausible explanations for the
majority of discrepancies, indicating that inaccurate
reporting was usually unintentional. All these data, with
data from partner interviews, ethnographic research, and
focus group discussions, were entered into a summary
database, coded, analyzed, and reported back to the trial
managers [30].
Composite measures are combinations of different
measures to generate a single outcome whose value falls
somewhere between outcomes from individual measures.
Composite measures may be generated from a single data
collection method (e.g., responses to a series of self-
reported adherence questions) or from different data col-
lection methods (e.g., a biomarker, product count, and a
self-reported measure.) The ADEPT (Adherence and Efﬁ-
cacy to Protease Inhibitor Therapy) study, a prospective
observational investigation of adherence to medication for
HIV suppression, examined the utility of such a measure.
The study sought to determine how adherent participants
would be when initiating HAART, the relationship
between adherence and virologic outcomes, any psycho-
logical factors that might predict adherence, and how dif-
ferent adherence measures compare with each other and,
possibly, predict virologic outcomes. A composite
adherence score (CAS) was developed based primarily on
data from electronic medication (MEMS
) bottle caps
containing a microchip recording each instance of bottle
opening; missing data were supplemented with pill counts
and self-reported adherence when MEMS data were
missing or inaccurate. The CAS indicated levels of
adherence higher than MEMS and lower than self-reported
or pill count and, most importantly, had a stronger corre-
lation with the primary objective measure, viral load sup-
pression, than any of its single components [20].
Baseline adherence predictors, as described earlier,
could provide valuable information to support or explain
trial results. Measuring an adherence predictor at baseline
helps preserve the role of randomization for an adjusted
analysis, thus ensuring that non-product-related predictors
of HIV infection are distributed in a balanced way across
study arms. Once measured, baseline adherence predictors
could be applied in secondary/conﬁrmatory analyses to
identify and remove participants who were likely to have
been non-adherent; removing even 5% of non-adherent
participants could greatly improve statistical power to
detect a treatment effect [31].
Examples of measures that might qualify as baseline
predictors include: an observed level of adherence to a
comparable product collected during a study run-in, a
validated self-efﬁcacy scale measured at screening, or the
recorded number of product insertions attempted by a
participant at her enrollment visit. Unfortunately, little
research has been conducted to identify and evaluate
potential baseline indicators of product adherence in clin-
ical trials. The design of the forthcoming Fem-PreP trial,
which will examine the safety and effectiveness of a once-
daily Truvada
 pill taken prophylactically to prevent HIV
transmission in women, includes a 2- to 4-week-long
vitamin run-in phase prior to randomization [32]. One
purpose of the run-in is for participants to practice pill-
taking and to allow for tailored counseling on adherence at
enrollment based on the participant’s experience. Another
purpose is to measure the ability of potential participants to
swallow a vitamin pill similar in size to Truvada
 in front
of staff at enrollment. Women who cannot do so will be
excluded. An evaluation of this baseline intervention could
provide valuable information about whether such run-in
behavior would or would not predict actual trial behavior.
Optimizing Adherence
There are several points at which adherence can be opti-
mized: (1) a priori, in both the overall design of the trial
and as explicitly crafted elements of that design; (2) in trial
implementation, beginning with recruitment, screening,
and enrollment; and (3) during the trial, in response to
1132 AIDS Behav (2010) 14:1124–1136
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Together, these somewhat overlapping categories indicate
that optimization of adherence must be both a very early
consideration and an ongoing dimension of trial
implementation.
Optimizing Adherence in Trial Design
CAPRISA 004
To date, at least one ongoing microbicide trial—the
CAPRISA 004 Phase 2B trial of tenofovir—has devel-
oped explicit strategies for optimizing adherence prior
to study initiation. The trial’s Adherence Support Pro-
gram (ASP) employs ‘‘job aids’’ (ﬂip charts, information
leaﬂets, and clock/calendar materials) and carefully
constructed messages to support the provision of per-
sonalized adherence counseling to trial participants [33].
CAPRISA participants are also given diaries in which to
record trial-related and other information. Though
optional, many women reportedly consult their diaries
when responding to behavioral questions during clinic
visits. A formal evaluation of the ASP is not currently
envisioned, but routine feedback from the clinical trial
team suggests that its personalized approach to counsel-
ing is time well spent.
Optimizing Adherence in Trial Implementation
Adherence Capacity
One approach to optimizing adherence would be to identify
and recruit the ‘‘right’’ people into the trial, that is, those
who appear to have both the appropriate risk proﬁle as well
as ‘‘adherence capacity’’. The run-in scenario used for the
Fem-PreP trial design, described in ‘‘Strategies to Improve
Adherence Measurement’’ above, offers one strategy for
identifying participants who may be more likely to adhere
to daily pill use through (1) observation of their pill-taking
abilities during enrollment and (2) assessing participants’
level of adherence during a run-in period. Still, without
prior evidence that this indicator of adherence capacity
could constitute a valid predictor of product use and
adherence in a trial context, clinical researchers may be
reluctant to predicate participant selection solely on such a
measure.
Optimizing Adherence in Response to Routine Monitoring
HPTN 035 As the HPTN 035 effectiveness trial of
BufferGel and PRO 2000 gels got under way, monitoring
efforts ﬂagged lower than targeted levels of gel adher-
ence. Thus, in early 2006, the protocol team met with
clinic staff to explore and address reasons for gel non-use.
These conversations revealed that some clinic staff were
conﬂating training messages that stressed the possibility
of gel side effects, the fact that gel efﬁcacy against HIV
infection was unknown, and the proven effectiveness of
condoms against pregnancy and HIV infection. As a
result, participants were receiving the following advice:
Since the gels may have side effects and may not protect
against HIV, only use the gels when you are also able to
use condoms. After consultation, the group revised its
adherence messages and developed associated scripts for
all sites to accord with the following message: In order to
properly test if the gel protects against HIV, it is
important that you use your gel during every sex act, even
when condom use is not possible. As a result, gel use,
overall and as a percentage of sex acts in which condoms
were also used, steadily increased, with the biggest gain
in gel adherence for sex acts in which a condom could
not be used [34]. This experience emphasizes the
importance of harmonizing risk reduction, contraception,
and product counseling, and ensuring that clinical trial
staff understand the associated messages thoroughly in
order to convey them accurately and persuasively to trial
participants.
Trajectory analyses, a statistical approach derived from
developmental psychology that reveals individual or group
behavioral patterns over time, may provide a useful
approach to monitoring adherence and identifying those
requiring assistance [35]. For example, while trajectory
analyses of self-reported gel adherence data from Savvy
Ghana and CONRAD CS trials identiﬁed a substantial
cluster of women reporting high, sustained gel use, other
clusters exhibited suboptimum adherence, including
approximately 10% of women reporting initially low but
increasing adherence, and 10–20% reporting declining gel
use [36]. And, when the high sustained condom users
identiﬁed in analysis of the Savvy Ghana trial were divided
into those reporting ‘‘perfect’’ (reported condom use
always equal to the number of sex acts in a given time
period) and ‘‘not-so-perfect’’ users, the ‘‘perfect’’ users
were signiﬁcantly more likely to have reported at least one
pregnancy during the trial [36]. This counter-intuitive
result suggests that participants who consistently report
100% product adherence are, in fact, likely to be over-
reporting adherence. Because the CONRAD CS trial had
collected sexual and adherence data by partner type, further
trajectory analysis based on gel use data with primary-
partners-only was able to discern an additional cluster of
low sustained gel users. Similar analysis from the MIRA
trial, which had enrolled mainly monogamous married
women, also identiﬁed four informative clusters, one con-
sisting of 31% of women classiﬁed as low sustained dia-
phragm users [26, 37].
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This paper drew from multiple sources to synthesize what
has been learned, at the bench and in the clinic, about
potential successes and limitations in achieving and mea-
suring microbicide adherence in clinical trials. We con-
clude with a set of six recommendations that we hope may
stimulate further improvements in both the measurement
and optimization of adherence for microbicide develop-
ment, and the ﬁeld of biomedical HIV prevention inter-
ventions more broadly.
Establish Clarity of Purpose a priori
Not all microbicide trials are measuring the same things,
particularly with respect to adherence, and consensus
continues to evolve around what should be measured, why,
how, and how often. Despite this variability, in all cases it
is essential to be clear a priori about the purpose, or pur-
poses, for which adherence-related data are to be collected.
Incorporate Adherence Measurement into Trial Design
and Analysis
Although the ITT analysis is, and will likely remain, the
gold standard for evaluating effectiveness in microbicide
trials, adherence-adjusted analyses offer the potential for
more powerful tests and richer understanding of trial data
and their implications. Recent advances in causal inference
may contribute greatly here, but more work is required to
fulﬁll this potential, notably by identifying pre-randomi-
zation factors associated with good trial-related product
adherence and more accurate assessments of adherence in
relation to exposure to HIV. Like the a priori conceptual-
ization of the role of adherence analyses in general, the
possibilities for adherence-adjusted analysis must also be
considered early in planning any trial or trial design
alternative.
Develop, Test, and Validate New Measurement
Approaches
More work is needed to develop, test and validate new
approaches to measuring adherence. One priority area is
the development of robust, validated biomarkers of
microbicide safety and adherence, requiring further work to
identify microbicide-induced changes in mucosa; assess
the impact of reproductive hormones, microﬂora, and
seminal plasma on microbicide-mucosa interactions; and
determine the effects of repeated microbicide exposure on
mucosa. As the microbicide ﬁeld focuses more intensely on
ART-based and coitally-independent products such as
vaginal rings, prospects for electronic or biochemical
methods for monitoring frequency of product use and
dosage seem more realistic and should be pursued.
A second priority area relates to the improvement of
indirect and self-reported approaches to adherence mea-
surement. This includes developing guidelines for tailoring
adherence-related questions (e.g., time references, formats
and data collection modes) to study populations; pursuing
efforts to identify and validate a composite measure of
adherence that would permit adherence comparisons across
trials; and improving strategies to identify and resolve
inconsistencies in reported sexual and adherence behavior
through triangulation techniques.
Optimize Adherence in Trial Settings
Optimizing adherence within the trial setting is of crucial
importance. Some strategies can be planned ahead. For
example, a run-in period can be designed, perhaps utilizing
the period between screening and enrollment, to collect
more baseline information on potential trial populations
with respect to the variables that are likely to be of primary
importance to study success. Counseling messages and
approaches should be shaped, tested, and modiﬁed to be
understood as a package prior to study implementation.
Explicit systems may be developed to support participants’
on-going adherence including (1) motivational enhance-
ment for those pre-identiﬁed as having adherence deﬁcits,
(2) provision of personal diaries; (3) use of adherence
‘‘buddies’’ or partners, and (4) individualized feedback on
observed adherence patterns. However, given the limited
availability of research to evaluate current approaches to
optimizing adherence, future trials should also incorporate
sufﬁcient ﬂexibility to monitor and adapt messages and/or
strategies as needed.
Plan for Cross-trial Data Collection and Data Sharing
All trials cannot collect data on all aspects and contexts of
adherence, but they may no longer need to do so. There is
now a body of social science literature that could be
compiled to serve all trials. It provides a deeper, more
detailed understanding about the categories of sexual
partners with whom topical gel use is or is not acceptable;
the constellation of reasons why use varies temporally; and
speciﬁc timing, dosage and insertion practices that might
affect test product safety and effectiveness. Further, with
respect to data sharing, when trials determine at the outset
the purpose(s) for which they will use adherence data, it
will be easier to develop strategies for sharing that infor-
mation with other trials, planned or under way, thereby
achieving economies of scale and helping accumulate a
body of common knowledge for various applications of
importance.
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Adherence
Guidelines are needed on what to report and how to ana-
lyze adherence measures. Some recommendations include:
conducting a thorough analysis of adherence patterns over
time before deeming time-averaged summary measures as
acceptable; carefully assessing potential biases of per-
protocol analysis and performing randomization-based
adherence-adjusted analyses when possible; and ﬁnally
retaining—rather than censoring, participants who go off
treatment or become pregnant in order to follow up their
behavior and outcome.
As emphasized in a recent IOM report, future trials
should consider partially-blinded factorial designs to
evaluate the utility of adherence interventions to inform
planning of future studies and forestall investments of time,
effort, and funding of approaches that are of doubtful yield
[10].
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